Date: 2014-09-22
Type of information: Initiation of development program
phase: preclinical
Announcement: initiation of the development program
Company: Sirona Biochem (Canada - France) Biogalenys (France)
Product: anti-aging compounds
Action mechanism:
Disease:
Therapeutic area:
Country:
Trial details:
Latest
news: * On September 22, 2014, Sirona Biochem has launched the next stage of development for its anti-aging compound library. With recent funding from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie, Sirona Biochem\'s subsidiary TFChem (France) moves into the next phase of the agreement with the French laboratory Biogalenys. Biogalenys has been chosen to work with the team of scientists at TFChem to develop the studies on the anti-aging technology. The research will provide preclinical data supporting multiple targeted applications using novel in vitro tests with varying stress conditions and cell types. The purpose is to both validate the compounds, and to satisfy the standard cohort of cosmetic safety studies. The data will then be used to determine the optimal commercial applications and joint venture partners.
